The finding is important because dry-cleaning facilities have historically used chemical solvents capable of affecting the nervous system. Although the industry has changed substantially over time, some solvents associated with garment cleaning and degreasing have been investigated for their persistence in indoor air, soil and groundwater. The new research does not establish that dry cleaners cause Parkinson’s disease, but it adds to a growing body of evidence exploring how long-term environmental exposures may intersect with neurological vulnerability.

Parkinson’s disease occurs when neurons involved in movement control progressively deteriorate, particularly dopamine-producing cells in a region of the brain called the substantia nigra. Dopamine is a chemical messenger that helps regulate the smooth initiation and coordination of movement. As dopamine-producing neurons are lost, people may develop tremor, muscle rigidity, slowed movement and balance problems. The disease can also involve sleep disturbances, changes in smell, constipation, depression and cognitive symptoms, sometimes years before the classic motor signs appear.

The biological connection between solvent exposure and Parkinson’s disease remains under investigation. Researchers have proposed several possible pathways, including oxidative stress, mitochondrial dysfunction, inflammation and the misfolding or impaired clearance of proteins inside nerve cells. Mitochondria function as the cell’s energy-producing machinery, and neurons are particularly dependent on stable energy supplies. If chemical exposure disrupts mitochondrial activity or increases the production of damaging reactive oxygen species, dopamine-producing neurons could become more vulnerable over time.

The nationwide study focuses on proximity, an approach that allows researchers to examine environmental patterns across large populations. Geographic proximity is commonly used in epidemiology as an indicator of potential exposure when direct measurements of individual chemical levels are unavailable. Investigators may compare where people live with the locations of businesses or environmental sources, then evaluate whether disease rates differ according to distance. Such methods can reveal population-level associations, but they cannot determine precisely how much of a chemical any particular person inhaled, absorbed through the skin or encountered through contaminated water or soil.

That distinction is central to interpreting the research. Living near a dry cleaner does not necessarily mean a person was exposed to hazardous concentrations of solvent. Facilities vary in their equipment, ventilation, chemical practices, operating history and compliance with environmental regulations. Exposure can also occur through other routes, including workplaces, household products, industrial sites and contaminated properties. A geographic association may therefore reflect a mixture of possible exposures rather than a single chemical or a single source.

The analysis also must contend with the complexity of Parkinson’s disease itself. Age is the strongest known risk factor, while genetic susceptibility, sex, occupational history, smoking patterns, socioeconomic conditions and access to medical care may influence diagnosis and disease reporting. People who live in dense urban areas may be more likely to live near commercial businesses and also more likely to encounter traffic pollution, industrial emissions or other environmental factors. Statistical adjustment can reduce the influence of these confounding variables, but observational studies cannot eliminate uncertainty completely.

What makes the research potentially influential is its nationwide scale and its focus on an everyday environmental setting rather than only on heavily contaminated industrial locations. Dry cleaners have existed in communities for decades, often embedded in residential and commercial neighborhoods. If proximity is consistently linked with Parkinson’s disease in additional studies, researchers may be able to investigate which historical practices, chemicals, exposure durations or building conditions are most relevant. That could guide environmental monitoring and help communities prioritize remediation.

The study’s implications extend beyond people who live near dry cleaners. Parkinson’s disease is increasingly viewed as the product of interactions between biology and environment rather than as a condition explained by one isolated cause. A person may carry genetic variants that alter how cells respond to toxins, while repeated low-level exposures over many years could contribute to cumulative stress. This gene–environment framework is still developing, but it offers a more realistic explanation for why individuals exposed to similar surroundings may experience different outcomes.

For now, the research should be read as a signal for further investigation, not as a reason for immediate alarm. More work will be needed to confirm the association in independent populations, reconstruct historical chemical exposures, distinguish between different types of dry-cleaning operations and examine whether risk changes with distance or duration of residence. Laboratory studies and carefully designed longitudinal research could also help determine whether the biological mechanisms proposed by scientists are plausible in humans. The central message is both striking and cautious: where people live may provide clues about Parkinson’s disease risk, but proximity alone cannot prove causation.

Subject of Research: Association between proximity to dry-cleaning facilities and the risk of Parkinson’s disease

Article Title: Nationwide association between proximity to dry cleaners and risk of Parkinson’s disease

Article References: Krzyzanowski, B., Beyene, K.M., Chirag, S.S. et al. “Nationwide association between proximity to dry cleaners and risk of Parkinson’s disease.” npj Parkinson’s Disease (2026). https://doi.org/10.1038/s41531-026-01513-6

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01513-6

Keywords: Parkinson’s disease, dry cleaners, environmental exposure, proximity, neurodegeneration, solvents, public health, epidemiology

Parkinson’s disease, a progressive neurodegenerative disorder characterized primarily by motor dysfunction and dopaminergic neuron loss in the substantia nigra, remains a formidable challenge for translational neuroscience. While numerous rodent models have contributed foundational insights, the translational gap persists, underscoring the limitations of these models in fully recapitulating human pathophysiology. NHPs, sharing closer anatomical, genomic, and neurophysiological traits with humans, offer a superior model to simulate the complexity of PD, including its motor and non-motor symptomatology, disease progression, and response to pharmacological interventions.

Central to this advocacy is the recognition that advancing therapeutic strategies necessitates more than just model availability; it requires a comprehensive ecosystem integrating sophisticated tools, cutting-edge resources, and robust ethical frameworks. Investment in the development of novel NHP models that precisely mimic human neurodegenerative trajectories is critical. Such models must incorporate the heterogeneity of PD presentations, encompassing genetic variants, environmental factors, and age-related vulnerabilities, to provide a more holistic platform for investigating disease mechanisms and testing candidate therapies.

Furthermore, the ethical considerations surrounding NHP research command meticulous attention. The cognitive complexity and social behaviors of these primates impose a moral imperative to ensure their welfare and minimize suffering. This necessitates the establishment of stringent ethical standards that govern experimental design, housing conditions, and enrichment protocols. Equally important is transparency and active public engagement, fostering societal trust and understanding regarding the essential role of NHPs in addressing pressing neurological health challenges.

The implementation of an international research consortium dedicated to NHP-based neurodegenerative research emerges as a strategic solution to amplify collaborative efforts, optimize resource allocation, and standardize methodologies. Such a consortium would serve as a hub for consolidating expertise across neuroscience, primatology, genomics, and bioethics, facilitating the exchange of knowledge and accelerating discovery. Pooling data and biological resources internationally would mitigate duplication and foster rapid iteration of experimental paradigms aligned with clinical relevance.

Modern neuroimaging modalities and neurophysiological tools uniquely synergize with NHP research. Techniques such as positron emission tomography (PET), functional magnetic resonance imaging (fMRI), and in vivo electrophysiology in awake, behaving primates provide unprecedented resolution into disease mechanisms at cellular and circuit levels. Coupling these approaches with advanced molecular profiling and gene editing technologies further enhances the capacity of NHP models to interrogate pathogenesis and therapeutic impact with translational precision.

The ageing process itself is a complex, systemic phenomenon influenced by genetic, epigenetic, and environmental factors, culminating in increased susceptibility to neurodegenerative diseases like PD. NHPs naturally manifest ageing phenotypes that parallel those in humans, including cognitive decline, motor dysfunction, and neuropathological hallmarks, making them ideal subjects to dissect the interplay between ageing and neurodegeneration. This naturalistic aspect is challenging to emulate in short-lived rodent models, highlighting the irreplaceable value of primates in ageing research.

In addressing PD and ageing, the integration of multidisciplinary perspectives—from molecular biology and systems neuroscience to behavioral science and ethics—within the NHP research framework is paramount. This holistic approach ensures that findings extend beyond isolated observations to form cohesive mechanistic models, ultimately informing the development of targeted, patient-specific interventions.

Moreover, technological advances in gene editing, such as CRISPR/Cas9, have opened avenues to engineer precise genetic mutations associated with familial and sporadic forms of PD in NHPs. This capability allows for creating models that mirror the genetic underpinnings of human disease, enabling investigation into gene-environment interactions and the evaluation of gene therapy strategies within a physiologically relevant context.

Funding agencies and governmental bodies are called upon to prioritize resource allocation towards these endeavors, recognizing the pivotal role of NHP research in bridging experimental findings and clinical application. Long-term investments are imperative to sustain colony maintenance, develop infrastructure, and nurture training programs dedicated to NHP neuroscience, ensuring a robust pipeline of skilled investigators.

Public outreach and education are equally vital components of this proposed paradigm. Transparent communication about the scientific necessity, ethical safeguards, and prospective benefits of NHP research fosters informed societal discourse and supports continued engagement. By demystifying research practices and outcomes, the scientific community can galvanize public support and counteract potential misconceptions or opposition.

The envisioned international consortium would also facilitate the adoption and harmonization of standardized protocols, ensuring reproducibility and comparability of findings across laboratories and countries. This standardization is critical to build a cohesive body of evidence that can more effectively propel translational pipelines and regulatory approvals for novel therapeutics.

In the face of escalating global demographic shifts towards older populations, the urgency of confronting neurodegenerative disorders intensifies. NHP research, when strategically expanded and ethically conducted, offers an unparalleled platform to dissect disease complexity and accelerate therapeutic discovery, ultimately aiming to alleviate the immense societal and economic burdens imposed by PD and related ageing disorders.

The confluence of biological relevant modeling, cutting-edge technology, ethical stewardship, and international collaboration predicates a new era of neuroscience research. Harnessing the unique capabilities of non-human primates holds the promise to unlock the mechanistic enigmas of Parkinson’s disease and the ageing brain, translating into tangible clinical advances that preserve function and quality of life in aging populations worldwide.

Subject of Research: Neurodegenerative diseases, Parkinson’s disease, ageing, non-human primate models

Article Title: Position paper: leveraging non-human primate (NHP) specificities to accelerate Parkinson’s disease and ageing research.

Article References:
Bezard, E., Anderson, R.M., Badin, R.A. et al. Position paper: leveraging non-human primate (NHP) specificities to accelerate Parkinson’s disease and ageing research. npj Parkinsons Dis. 11, 227 (2025). https://doi.org/10.1038/s41531-025-01088-8

Image Credits: AI Generated